Assessing ChatGPT-4 as a clinical decision support tool in neuro-oncology radiotherapy: a prospective comparative study - Top-Institutions - MDSpire

Assessing ChatGPT-4 as a clinical decision support tool in neuro-oncology radiotherapy: a prospective comparative study

  • By

  • Paolo Tini

  • Federica Novi

  • Flavio Donnini

  • Armando Perrella

  • Giulio Bagnacci

  • Maria Antonietta Mazzei

  • Giuseppe Minniti

  • October 15, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Neuro-Oncology
    • Medical AI Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Neuro-Oncology
    • Clinical AI Integration

  • #3

    Dana-Farber/Brigham and Women’s Cancer Center
    Dana-Farber/Brigham and Women’s Cancer Center

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Neuro-Oncology
    • AI in Oncology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-Oncology
    • Radiation Oncology
    • Medical Informatics

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Radiation Oncology
    • Neuro-Oncology
    • AI in Clinical Practice

Original Source(s)

Assessing ChatGPT-4 as a clinical decision support tool in neuro-oncology radiotherapy: a prospective comparative study

  • by Paolo Tini, Federica Novi, Flavio Donnini, Armando Perrella, Giulio Bagnacci, Maria Antonietta Mazzei, Giuseppe Minniti

  • October 15, 2025

Related Content

Evaluation of a 3D C-Vit Model for Enhanced Grading of Pediatric Brain Tumors: Interpretability and Performance Insights

Work Reintegration Following Low-Grade Glioma Treatment: Evaluating Return Rates and Identifying Patient Challenges

Diagnostic accuracy of 1H-MRS in detecting the oncometabolite 2-hydroxyglutarate (2HG) in adult-type diffuse gliomas